The Leeds Teaching Hospitals NHS Trust

A new purpose-built clinical research facility is coming to Leeds

12 February 2019

Leeds Teaching Hospitals NHS Trust is delighted to announce that work has started on a new £3-million purpose built National Institute for Health Research (NIHR) Clinical Research Facility (CRF) development which will transform the care available for patients taking part in clinical trials.

Leeds Teaching Hospitals (LTHT) is committed to supporting and increasing research and innovation. There is clear evidence that patients cared for in hospitals with a high volume of research activity have better overall health outcomes than less research active organisations.

Based in Bexley Wing on the St James’s University Hospital site, the new facility will double the amount of space available for research trials, provide a more spacious, more comfortable and better equipped environment for patients.

The Leeds CRF, a designated National Institute for Health Research (NIHR) facility, will comprise 18 patient chair/beds treatment delivery area, consulting rooms and supportive clinical care space to deliver high quality outpatient, day case and inpatient treatment and care.

Several thousand patients take part in early experimental clinical trials supported by the CRF at LTHT every year, and many will visit our facilities a number of times over a period of months to receive novel treatments or interventions and enable close safety observation.

CRF launch

Professor Chris Twelves, CRF Clinical Director, says: “Patients taking part in clinical trials give up precious time to contribute to health research and innovation for future patient and public benefit. The new, state-of-the-art CRF will transform the experience of patients taking part in clinical trials.

The new development will also help us to take on more trials, which means we’ll be able to offer more and more patients from Leeds and across the region access to new emerging technologies and medication.”

Our patients provide us with very positive feedback on their experience with us and we are confident that the new CRF will allow many more patients to take part in and benefit from clinical trials in the future. 

Sheila Walker 

Sheila2Sheila is currently undergoing cycle eight of the CARBON trial for breast cancer under the care of Prof Chris Twelves, Consultant in Clinical Oncology.

“Taking part in research has been amazing and I feel honoured to be giving something back. My care in Leeds has been tremendous and the love and personal care I have received from the team has made it a more pleasant journey. I feel like I am part of a family and I appreciate the little things the team do and ask about when I visit for treatment.”

Sheila would tell anyone thinking of taking part in a trial to go for it. “Why not? It’s great to contribute to research, and it is something I am very proud of - you shouldn’t be scared.”

“I am absolutely thrilled about the new CRF, it’s another feather in the cap of the hospital which will help to see great advances and put us at the top for research.”


Chris Stocks 

Chris2Chris was diagnosed with multiple myeloma in 2010. In July 2014 he was the first person in the UK to start a trial for a drug called daratumumab. After 12 months he had no signs of the disease and has had the all clear for three years.

“The team in Leeds have been superb and second to none. I have received consistent care and consideration from everyone.

I would tell anyone thinking about taking part in research to say yes! There is no advancement without trials and even if they don’t work for you the research will benefit others.

The new CRF is great for the region as people travel from all over the country for care in Leeds. It’s a tremendous bonus that will benefit patients for many years to come.”


Paul Brewer 

Paul2Paul was diagnosed with a brain tumour 2.5 years ago and received a terminal diagnosis of less than a year.

Under the care of Prof Susan Short, Consultant in Clinical Oncology at Leeds Cancer Centre he underwent tests and had the genetic marker needed to start the ABT414 trial. He had chemotherapy and radiotherapy alongside receiving the trial drug.

Following the trial he now has no sign of the tumour. This has given him more time to spend with his family including his wife and 11 year old son.

“The care I have received has been gold standard and I cannot praise Prof Short and the research nurses enough.

I would tell anyone thinking of taking part in research to go for it - you have nothing to lose and I wouldn’t be here without it.

I am excited about the prospect of more trials happening once the new CRF is completed. With this extra capacity I hope that if the tumour did come back I would be able to take part in other trial.”